Diagnosis and treatment of pulmonary hypertension;Diagnóstico y tratamiento de la hipertensión pulmonar

Revista Clinica Espanola

Volumn 208, Issue 3, 2008, Pages 142-155

  Sanchez Roman J ^a,b   Garcia Hernandez F J ^a   Castillo Palma, M J ^a   Ocana Medina C ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b 3 ^*  (Spain)

Author keywords

Diagnosis; Pulmonary arterial hypertension; Treatment

Indexed keywords

AMBRISENTAN; ANOREXIGENIC AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE; SITAXSENTAN; UNIPROST;

ANTICOAGULANT THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL HEART DISEASE; CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; ELECTROCARDIOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG BIOPSY; LUNG FUNCTION TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTAL HYPERTENSION; PULMONARY HYPERTENSION; REVIEW; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 42549171603     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1157/13115823     Document Type: Review

References (71)

1. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewsk H, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:S40-7.
2. e Symposium mondial sur l'hypertension artérielle pulmonaire. Venise, Italie, 23-25 juin 2003. Rev Med Int. 2003;24:853-6.
3. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115:343-9.
4. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al Pulmonary arterial hypertension in France. Result from a National Registry. A J Resp Crit Care Med. 2006;173:1023-30.
5. Morales JE, Campos JR, Rosas MJR. Proceso diagnóstico en la hipertensión arterial pulmonar. Neumología y Cirugía de Tórax. 2006;65Supl4:S28-42.
6. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:S14-34.
7. Hegewald MJ, Markewitz B, Elliott CG. Pulmonary hypertension: clinical manifestations, classification and diagnosis. Int J Clin Pract. 2007;61Suppl156):5-14.
8. Hernández C, Mejía R, Rosas MJR, Campos R, Morales JE. Evaluación funcional en la hipertensión arterial pulmonar. Neumología y Cirugía de Tórax. 2006;65Supl4:S51-7.
9. Gómez Navarro C, Ocaña Medina C, Martínez Martínez A, Cayuela Domínguez A, Sánchez Román J. Evaluación funcional del ventrículo derecho en hipertensión pulmonar mediante el índice Tei. Rev And Card. 2004;39:36.
10. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003;48:516-22.
11. Mukerjee D, St. George D, Knight C, Davar J, Wells UA, Du Bois RM, et al. Ecocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology. 2004;43:461-6.
12. Steen V. Advancements in diagnosis of pulmonary arterial hypertension in scleroderma. Arthritis Rheum. 2005;52:3698-700.
13. Fernández J, Zulueta T, Reyes JR, Castillo MJ, Sánchez-Román J. Pulmonary capillary hemangiomatosis as cause of pulmonary hypertension in a young woman with clinical an biological criteria of systemic lupus erythematosus. J Rheumatol. 1998;26:231-3.
14. Coulden R. State-of-the-art imaging techniques in chronic thromboembolic pulmonary hypertension. Proc Am Thor Soc. 2006;3:577-83.
15. Bergin CJ, Hauschildt J, Rios G, Belezzuoli EV, Huynh T, Channick RN. Accuracy of MR angiography compared with radionuclide scanning in identifying the cause of pulmonary arterial hypertension. Am J Roentgenol. 1997;168:1549-55.
16. Marcu CB, Beek AM, Van Rossum AC. Cardiovascular magnetic resonance imaging for the assessment of right heart involvement in cardiac and pulmonary disease. Heart Lung Circulation. 2006;15:362-70.
17. Saba TS, Foster J, Cockburn M, Cowan M, Peacock AJ. Ventricular mass index using magnetic resonance imaging accurately estimates pulmonary artery pressure. Eur Respir. J 2002;20:1519-24.
18. Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol. 2004;43SupplS:48S-55S.
19. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000;161:487-92.
20. García Hernández F, Ocaña Medina C, González. León R, Garrido Rasco R, López Pardo F, Rodríguez Puras M, et al. Resultados de un programa de detección de hipertensión pulmonar mediante ecocardiografía-Doppler en una serie de pacientes con esclerodermia. Rev Clin Esp. 2005;205Supl2:145.
21. García Hernández FJ, Sánchez Román J, Ocaña Medina C, Mateos Romero L. Hipertensión arterial pulmonar primaria en un paciente con neurofibromatosis. Med Clín (Barc). 2002;118:78.
22. García Hernández FJ, Ocaña-Medina C, González León R, Garrido Rasco R, Sánchez Román J. Autoimmune polyglandular syndrome and pulmonary arterial hypertension. Eur Respir J. 2006;27:657-8.
23. McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126Suppl1:S78-92.
24. Rubin LJ. Primary pulmonary hypertension. Chest. 1993;104:236-50.
25. Garrido Rasco R, González León R, Cabrera Pérez R, Ocaña Medina C, García Hernández FJ, Colorado Bonilla R, et al. Características histológicas de las lesiones vasculares en la hipertensión arterial pulmonar asociada a enfermedades autoinmunes sistémicas. Rev Clin Esp. 2006;206Supl1:166-7.
26. Galié N. Pulmonary hypertension 2006: definitions and classification. Kardiol Pol. 2006;64Suppl1:5-8.
27. Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Int Med. 2005;258:199-215.
28. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984;70:580-7.
29. Robbins IM, Kawut SM, Yung D, Reilly MP, Lloyd W, Cunningham G, et al. A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. Eur Respir J. 2006;27:578-84.
30. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.
31. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994;121:409-15.
32. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. Acomparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-301.
33. Saphiro SM, Oudiz J, Cao T, Romano MA, Beckmann J, Georgio D, et al. Primary pulmonary hypertension: inproved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol. 1997;30:343-9.
34. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780-8.
35. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension. The impact of epoprostenol therapy. Circulation. 2002;106:1477-82.
36. Higenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L. Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart. 1998;80:151-5.
37. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, et al, for the Aerosolized iloprost randomized study group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-9.
38. Olschewski H, Nikkho S, Behr J, Borst M, Ewert R, Höper M, et al. Long-term survival in patients with pulmonary hypertension inhaling iloprost (AIR-2 study).(Abstract). Vienna: Europ Soc Cardiol Congress; 2003.
39. Hoeper MM, Spiekerkoetter E, Westerkamp V, Gatzke R, Fabel H. Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension. Eur Respir J. 2002;20:339-43.
40. Vachiery JL, Lang I, Gómez Sánchez MS, Kneussl M, Escribano P, Naeige R. Subcutaneous treprostinil therapy evokes both survival benefit and continuous dose dependent efficacy improvements in patients with pulmonary arterial hypertesion. A long term European multicentre analysis of 112 patients. ACC Congress; 2004.
41. Lang I, Gómez-Sánchez M, Kneussl M, Naeije R, Escribano P, Skoro-Sajer N, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest. 2006;129:1636-43.
42. Barst RJ, Galiè N, Naeije R, Simonneau G, Jeffs R, Arneson C, et al. Long-term outcome in pulmonary arterial hypertension patients treated with treprostinil. Eur Respir J. 2006;28:1195-203.
43. Barst RJ, McGoon M, McLaughlin V, Tapson V, Oudiz R, Shapiro S, et al. Beraprost therapy for pulmonary arterial hypertension.J Am Coll Cardiol. 2003;41:2119-25.
44. Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A, et al (BREATHE-1). Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
45. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005;25:244-9.
46. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart. 2006;92:926-32.
47. McLaughlin VV. Survival in patients with primary pulmonary hypertension treated with first-line bosentan. Eur J Clin Invest. 2006;36Suppl3:10-5.
48. Weber C, Banken L, Birnboeck H, Schulz R. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol. 1999;39:847-54.
49. Barst RJ, Rich S, Horn EM, McLaughlin V, McFarland J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: Open-label pilot study. Chest. 2002;121:1860-8.
50. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169:441-7.
51. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006;47:2049-56.
52. Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant. 2007;26:63-9.
53. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46:529-35.
54. Galié N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesh D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-57.
55. Galiè N, Burgess G, Parpia T, Barst R. Effects of sildenafil on 1-year survival of patients with idiopathic pulmonary arterial hypertension (PAH). Proc Am Thorac Soc. 2005;2:A802.
56. Fernández MA, Roma E. International normalized ratio (INR) increase in patients taking oral anticoagulant therapy (OAT) and using sildenafilo. Haematologica. 2003;88:ELT34.
57. Kataoka M, Satoh T, Manabe T, Anzai T, Yoshikawa T, Mitamura H, et al. Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. Circ J. 2005;69:461-5.
58. García Hernández FJ, Ocaña Medina C, Martínez Martínez A, Bautista Lorite A, Santos Ramos B, Sánchez Román J. Tratamiento combinado con prostaciclina intravenosa y sildenafilo en pacientes con hipertensión pulmonar. Med Clin (Barc). 2004;122:64-6.
59. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.Am J Respir Crit Care Med. 2006;174:1257-63.
60. Humbert M, Barst RJ, Robbins IM, Channick RN, Galie N, Boonstra A, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24:353-9.
61. Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol. 2006;48:1433-7.
62. Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T, Zaiman A, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension Eur Respir J. 2007;29:469-75.
63. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J. 2005;26:858-63.
64. Ishikura K, Yamada N, Ito M, Ota S, Nakamura M, Isaka N, et al.Beneficial acute effects of rhokinase inhibitor in patients with pulmonary arterial hypertension. Circ J. 2006;70:174-8.
65. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med. 2005;353:1412-3.
66. Kao PN. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest. 2005;127:1446-52.
67. Henriques-Coelho T, Roncon-Albuquerque R, Lourenço AP, Baptista MJ, Oliveira SM, Brandão-Nogueira A, et al. Ghrelin reverses molecular, structural and hemodynamic alterations of the right ventricle in pulmonary hypertension. Rev Port Cardiol. 2006;25:55-63.
68. Taraseviciene-Stewart L, Scerbavicius R, Stewart JM, Gera L, Demura Y, Cool C, et al. Treatment of severe pulmonary hypertension: a bradykinin receptor-2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy. Peptides. 2005;26:1292-300.
69. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest. 2003;111:1339-46.
70. McMurtry MS, Bonnet S, Wu X, Dyck JRB, Haromy A,Hashimoto K, et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res. 2004;95:830-40.
71. Pozeg ZI, Michelakis ED, McMurtry S, Thébaud B, Wu X, Dyck JRB, et al. In vivo gene transfer of theO2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation. 2003;107:2037-44.